ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,048.42
-0.46%
US Tech 100
17,150.40
1.02%
Dow Jones
38,085.80
0.00%
Brent Oil
88.53
0.43%
Bitcoin
64,288.16
-0.30%
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Gossamer Bio Inc (GOSS) Quote

Gossamer Bio Inc

Gossamer Bio Inc (GOSS)

NASDAQ
0.67
-0.0383
(-5.41%)
Closed April 25 4:00PM
Delayed by 15 minutes
0.7035
0.0335
( 5.00% )
Pre Market: 8:09AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.7035
Bid
0.67
Ask
0.69
Volume
169
0.00 Day's Range 0.00
0.4525 52 Week Range 1.88
Market Cap
151.14M
Previous Close
0.67
Open
-
Last Trade
125
@
0.7035
(formt)
Last Trade Time
08:09:41
Financial Volume
-
VWAP
-
Average Volume (3m)
1,430,846
Shares Outstanding
225,582,250
Dividend Yield
-
PE Ratio
-0.84
Earnings Per Share (EPS)
-0.8
Revenue
-
Net Profit
-179.82M

About Gossamer Bio Inc

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth,... Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.gossamerbio.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Gossamer Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GOSS. The last closing price for Gossamer Bio was $0.67. Over the last year, Gossamer Bio shares have traded in a share price range of $ 0.4525 to $ 1.88.

Gossamer Bio currently has 225,582,250 shares outstanding. The market capitalization of Gossamer Bio is $151.14 million. Gossamer Bio has a price to earnings ratio (PE ratio) of -0.84.

GOSS Latest News

More News

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

March 12 2024
Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans

March 05 2024
Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

March 05 2024
Edgar (US Regulatory)

Form 8-K - Current report

March 05 2024
Edgar (US Regulatory)

Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

- First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study - - Inclusion of Japan in Phase 3 PROSERA Study Following CTN Acceptance by PMDA - - Cash, cash equivalents and...

March 05 2024
Business Wire

Form 8-K - Current report

March 04 2024
Edgar (US Regulatory)

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

January 08 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

January 04 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0965-12.06250.80.84990.633312916120.71382907CS
4-0.4765-40.38135593221.181.280.633314961690.95245219CS
12-0.1076-13.26593514980.81111.60.633314308461.15010021CS
260.200839.94430077580.50271.60.46315091010.9589434CS
52-0.4165-37.18751.121.880.452518699711.06218233CS
156-7.6165-91.54447115388.3215.1950.452517839043.8214859CS
260-15.5465-95.670769230816.2527.14970.452512897115.47554881CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TVGNTevogen Bio Holdings Inc
$ 1.54
(81.18%)
4.4M
PEGYPineapple Energy Inc
$ 0.083
(59.92%)
83.5M
FRGTFreight Technologies Inc
$ 1.3201
(44.48%)
7.79M
KTRAKintara Therapeutics Inc
$ 0.2055
(30.06%)
6.81M
GGLLDirexion Daily GOOGL Bull 2X ETF
$ 43.98
(22.10%)
13.62k
ZENVZenvia Inc
$ 1.67
(-24.09%)
5
AHGAkso Health Group
$ 0.60
(-22.08%)
10
ANLAdlai Nortye Ltd
$ 10.80
(-19.76%)
2
NSYSNortech Systems Inc
$ 14.00
(-19.08%)
2
VINCVincerx Inc
$ 0.735
(-18.03%)
180.21k
PEGYPineapple Energy Inc
$ 0.083
(59.92%)
83.5M
IVPInspire Veterinary Partners Inc
$ 0.0427
(12.07%)
11.08M
FRGTFreight Technologies Inc
$ 1.3201
(44.48%)
7.79M
KTRAKintara Therapeutics Inc
$ 0.2055
(30.06%)
6.81M
TVGNTevogen Bio Holdings Inc
$ 1.54
(81.18%)
4.4M

GOSS Discussion

View Posts
FlippinNDippin FlippinNDippin 2 weeks ago
Took a starter here. GLTA
👍️0
Monksdream Monksdream 1 month ago
GOSS under $2
👍️0
glenn1919 glenn1919 1 month ago
GOSS..........................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
GOSS..................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
GOSS......................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 months ago
GOSS under $2
👍️0
Monksdream Monksdream 7 months ago
GOSS new 52 week low
👍️0
Monksdream Monksdream 7 months ago
GOSS new 52 week low
👍️0
Monksdream Monksdream 7 months ago
GOSS new 52 week low
👍️0
Dutch4 Dutch4 1 year ago
Agreed!
👍️0
hippityhop hippityhop 1 year ago
Institutionals shorting this unmercilessly. Three trades totalling 2.4M total shares bought at 4 pm. @ .20 cent profit a share come to $468k.
👍️0
hippityhop hippityhop 1 year ago
This is a 100/200 percenter in next 3 months, buy this now or weep later!!
👍️0
crudeoil24 crudeoil24 2 years ago
Raymond James Initiates Coverage On Gossamer Bio with Outperform Rating, Announces Price Target of $19
7:13 am ET April 18, 2022 (Benzinga) Print
Raymond James analyst Timur Ivannikov initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $19.

Latest Ratings for GOSS DateFirmActionFromTo

Nov 2021SVB LeerinkMaintainsOutperform Aug 2021SVB LeerinkMaintainsOutperform Mar 2021HC Wainwright & Co.ReiteratesBuy
👍️0
crudeoil24 crudeoil24 2 years ago
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company's product candidates include Seralutinib (GB002), GB004, GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB004 is a gut-targeted, oral small molecule being developed for the treatment of inflammatory bowel disease (IBD). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS).
👍️0

Your Recent History

NASDAQ
GOSS
Gossamer Bio
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved